CN-121971444-A - Application of 5-nitro-8-hydroxyquinoline

Abstract

An application involving 5-nitro-8-hydroxyquinoline is provided. In particular to an application of 5-nitro-8-hydroxyquinoline, pharmaceutically acceptable salt, crystal form, solvate, isotopic derivative or prodrug thereof in preparing antiviral drugs. The 5-nitro-8-hydroxyquinoline, the pharmaceutically acceptable salt, the crystal form, the solvate, the isotopic derivative or the prodrug thereof have remarkable activity in resisting human papilloma virus.

Inventors

• DENG YIJUN

Assignees

• 江苏亚虹医药科技股份有限公司
• 上海亚虹医药科技有限公司

Dates

Publication Date

20260505

Application Date

20220530

Priority Date

20210531

Claims (8)

1. 1. Use of any one selected from the group consisting of: 5-nitro-8-hydroxyquinoline, pharmaceutically acceptable salts thereof, crystalline forms thereof, solvates thereof, isotopic derivatives thereof, prodrugs thereof; the virus is human papilloma virus.
2. 2. Use according to claim 1, the antiviral medicament being for use in a mammal, preferably a human.
3. 3. The use according to claim 1 or 2, wherein the virus is selected from any one or a combination of human papillomavirus 6 (Human Papillomavirus, HPV 6), human papillomavirus 11 (Human Papillomavirus, HPV 11), human papillomavirus 16 (Human Papillomavirus, HPV 16) and human papillomavirus 18 (Human Papillomavirus, HPV 18).
4. 4. A use according to any one of claims 1 to 3, wherein: the prodrug is (S) - (5-nitroquinolin-8-yloxy) methyl 1-isopropylpyrrolidine-2-carboxylate.
5. 5. A method of preventing or treating a viral infection comprising the steps of: administering to the subject a prophylactically or therapeutically effective amount of 5-nitro-8-hydroxyquinoline, a pharmaceutically acceptable salt thereof, a crystalline form thereof, a solvate thereof, an isotopic derivative thereof, or a prodrug thereof; the virus is human papilloma virus; The subject is a mammal, preferably a human.
6. 6. A method of in vitro disinfection comprising the steps of: the environment or object to be treated is contacted with an effective amount of 5-nitro-8-hydroxyquinoline, a pharmaceutically acceptable salt thereof, a crystalline form thereof, a solvate thereof, an isotopic derivative thereof.
7. 7. The method of claim 5 or 6, wherein the virus is selected from any one or a combination of human papillomavirus 6 (Human Papillomavirus, HPV 6), human papillomavirus 11 (Human Papillomavirus, HPV 11), human papillomavirus 16 (Human Papillomavirus, HPV 16) and human papillomavirus 18 (Human Papillomavirus, HPV 18).
8. 8. A pharmaceutical composition for treating a viral infection comprising: -pharmaceutically acceptable excipients, and -Any one selected from the group consisting of 5-nitro-8-hydroxyquinoline, a pharmaceutically acceptable salt thereof, a crystalline form thereof, a solvate thereof, an isotopic derivative thereof, a prodrug thereof; the virus is human papilloma virus; Preferably, the virus is selected from any one or a combination of human papillomavirus 6 (Human Papillomavirus, HPV 6), human papillomavirus 11 (Human Papillomavirus, HPV 11), human papillomavirus 16 (Human Papillomavirus, HPV 16) and human papillomavirus 18 (Human Papillomavirus, HPV 18); preferably, the prodrug is (S) - (5-nitroquinolin-8-yloxy) methyl 1-isopropylpyrrolidine-2-carboxylate.

Description

Application of 5-nitro-8-hydroxyquinoline The application claims priority of the China patent application (application number 2021106017773) of 31/05/2021, which is a divisional application of the China patent application (application number 2022800183414 application of 5-nitro-8-hydroxyquinoline) submitted by 30/05/2022. Technical Field The present disclosure relates to the fields of organic chemistry, medicine, antiviral therapy. In particular to the application of 5-nitro-8-hydroxyquinoline. Background Human Papillomaviruses (HPV) are a DNA virus belonging to the family papillomaviridae, a very common class of viruses worldwide. HPV members have mucosal epithelium and cutaneous epithelial tropism, and can cause various genital tract diseases such as genital warts, and various malignant tumors including cervical cancer, penile cancer, anal cancer, oral cancer, throat cancer, tonsil cancer, esophageal cancer, and the like. Human papillomaviruses are of more than 100 types, at least ten of which can cause cancer, and are the most important of the human oncological viruses. The virus has high infection rate and strong pathogenicity, and has great harm to people, especially women, thereby attracting wide attention in medical circles at home and abroad. Currently, there are clinically available prophylactic multivalent vaccines (HPV 6,11,16,18, etc.) that can prevent infection by multiple viral types, but there is no significant therapeutic effect on the infected patient using the prophylactic vaccine. The development of effective medicaments for targeting various types of HPV can provide a new method for clinically treating and preventing human papilloma virus related diseases including malignant tumors. Currently, there remains a need in the art for effective drugs against HPV. Disclosure of Invention The technical problem to be solved by the present disclosure is to provide an application of 5-nitro-8-hydroxyquinoline, a pharmaceutically acceptable salt thereof, a crystal form thereof, a solvate thereof, an isotopic derivative thereof or a prodrug thereof in preparing antiviral drugs, especially in preparing anti-Human Papilloma Virus (HPV) drugs. The technical problems are solved by the following technical scheme: In a first aspect, the present disclosure provides the use of 5-nitro-8-hydroxyquinoline, a pharmaceutically acceptable salt thereof, a crystalline form thereof, a solvate thereof, an isotopic derivative thereof, or a prodrug thereof in the preparation of an antiviral medicament. Preferably, the antiviral drug is for use in mammals, preferably humans. Preferably, the virus is one or more of human papillomavirus, preferably human papillomavirus 6 (Human Papillomavirus, HPV 6), human papillomavirus 11 (Human Papillomavirus, HPV 11), human papillomavirus 16 (Human Papillomavirus, HPV 16) and human papillomavirus 18 (Human Papillomavirus, HPV 18). In a second aspect, the present disclosure provides a 5-nitro-8-hydroxyquinoline, a pharmaceutically acceptable salt thereof, a crystalline form thereof, a solvate thereof, an isotopic derivative thereof, or a prodrug thereof for use in treating a viral infection. Preferably, the present disclosure provides a 5-nitro-8-hydroxyquinoline, a pharmaceutically acceptable salt thereof, a crystalline form thereof, a solvate thereof, an isotopic derivative thereof, or a prodrug thereof for use in treating a viral infection in a mammal. Wherein the mammal is preferably a human. Preferably, the virus is one or more of human papillomavirus, preferably human papillomavirus 6 (Human Papillomavirus, HPV 6), human papillomavirus 11 (Human Papillomavirus, HPV 11), human papillomavirus 16 (Human Papillomavirus, HPV 16) and human papillomavirus 18 (Human Papillomavirus, HPV 18). In a third aspect, the present disclosure provides a method of treating a viral infection comprising the step of administering to a subject a therapeutically effective amount of 5-nitro-8-hydroxyquinoline, a pharmaceutically acceptable salt thereof, a crystalline form thereof, a solvate thereof, an isotopic derivative thereof, or a prodrug thereof. Preferably, the present disclosure provides a method of treating a viral infection in a mammal comprising the step of administering to a subject a therapeutically effective amount of 5-nitro-8-hydroxyquinoline, a pharmaceutically acceptable salt thereof, a crystalline form thereof, a solvate thereof, an isotopic derivative thereof, or a prodrug thereof. Wherein the mammal is preferably a human. Preferably, the virus is one or more of human papillomavirus, preferably human papillomavirus 6 (Human Papillomavirus, HPV 6), human papillomavirus 11 (Human Papillomavirus, HPV 11), human papillomavirus 16 (Human Papillomavirus, HPV 16) and human papillomavirus 18 (Human Papillomavirus, HPV 18). In a fourth aspect, the present disclosure provides a pharmaceutical composition for treating a viral infection comprising 5-nitro-8-hydroxyquinoline, a pharmaceutically ac